Abirapro 250 mg is a tablet identified as containing 250 mg of abiraterone acetate. Available product listings associate it with Glenmark Pharmaceuticals Ltd.
Abiraterone acetate is a prodrug converted to abiraterone, an inhibitor of CYP17A1 involved in androgen production.
It is used in specified metastatic prostate-cancer treatment settings, including mCRPC and high-risk metastatic castration-sensitive disease under current U.S. labeling.
Both contain abiraterone acetate, but they are distinct branded products. Product-specific manufacturer, formulation, packaging and authorization details can differ.
Available medicine listings identify Glenmark Pharmaceuticals Ltd. as the manufacturer/marketer.
The underlying scientific development originated at the Institute of Cancer Research, followed by licensing and commercial development by Cougar Biotechnology.
Zytiga is the established reference product containing abiraterone acetate.
Current U.S. labeling uses 1,000 mg once daily for the principal metastatic prostate-cancer indications.
Four 250 mg tablets contain a total of 1,000 mg abiraterone acetate.
No. Current U.S. labeling requires administration on an empty stomach, with no food for 2 hours before and 1 hour after the dose.
Food can substantially increase abiraterone exposure, potentially changing safety and tolerability.
Abiraterone alters steroid production through CYP17 inhibition and can produce mineralocorticoid-related effects. Prednisone or prednisolone is incorporated into labeled regimens to help manage these effects.
Current U.S. labeling states that patients should receive a GnRH analog concurrently or have undergone bilateral orchiectomy.
Potential effects include hypertension, hypokalemia, fluid retention, edema, fatigue, gastrointestinal symptoms and liver-test abnormalities.
Yes. Hepatotoxicity is a recognized important risk and liver-function monitoring is required.
Yes. Hypertension is associated with mineralocorticoid effects from CYP17 inhibition.
Yes. Hypokalemia is a recognized adverse effect.
Yes. Fluid retention and edema can occur because of mineralocorticoid effects.
Cardiac effects are recognized, particularly in patients with cardiovascular risk factors.
Yes. Current U.S. labeling provides a lower starting dose for patients with baseline moderate hepatic impairment.
Abiraterone acetate is a prescription anticancer medicine. The exact legal supply requirements depend on the jurisdiction.
Check the product name, active ingredient, strength, manufacturer, batch/lot number, expiry information and applicable authorization details against reliable documentation.
No. Dose changes should be made by the treating healthcare professional.
Abiraterone is intended for specified prostate-cancer treatment in men. Pregnancy and reproductive exposure require strict precautions.
The applicable national regulatory label, DailyMed record or EMA product information should be consulted for the complete authoritative document.